Panel Agrees: 2 LDL Receptor Patents Are Not Sufficiently Enabled
WASHINGTON, D.C. — In a blow to Amgen Inc. and two subsidiaries, the Federal Circuit U.S. Court of Appeals on Feb. 11 upheld findings by a federal judge in Delaware that...To view the full article, register now.
Already a subscriber? Click here to view full article